The triplet carfilzomib, immunomodulatory drugs, and dexamethasone has shown effective outcomes for the treatment of relapsed/refractory (R/R) multiple myeloma.
Apart from this, for numerous authorities, this combination has a little bit of a high cost. On behalf of new data, this triplet (carfilzomib, thalidomide, and dexamethasone) could be a safe as well as a cost-effective alternative.
The carried out study enrolled patients with relapsed/refractory MM who had between 1 to 3 prior lines of treatment. Total 83 of the patients had a median age of about 66 years. Patients were taken 12 cycles, each lasting one month, of this triplet.
The main result that is measured at the end of a study in order to see if a given treatment worked was PFS (Progression-Free Survival). Secondary endpoints were ORR (Overall Response Rate), OS (Overall Survival), SE (side effects), and QoL (Quality of Life).
The median progression-free survival was noted as 20 months. The progression free survival rate at 6.5 months was noted as 76.2%. Median OS has not been achieved in the carried out study. The combination achieved an overall response rate of 86.4%.
Maximum side effects noted in the study population were grade 2 or lower. The most commonly reported side effects were peripheral neuropathy, with 16% of patients reporting, followed by upper respiratory tract infections in 12% of patients. Those most recent data indicates that 41% of patients have completed 18 cycles of treatment.
An interview was held in between Targeted Oncology and Hang Quach, MD, a consultant clinical and laboratory haematologist at St. Vincent’s Hospital, in which Hang Quach discussed the phase-II Australasian Leukaemia and Lymphoma Group multiple myeloma 018/ Asian Myeloma Network 002 study and how it can be responsible for impacting the treatment of relapsed/refractory MM in the future.
Reference:
